LATEST ONCOPRESCRIBE UPDATES
ENHERTU® Effective Against Brain Metastases in Patients with HER2+ Breast Cancer
FDA Approves Perioperative OPDIVO® in Resectable Lung Cancer
Late Breaking Abstract – ESMO 2024: Adjuvant KISQALI® Shows Deepening Benefit in Patients with Early Stage Breast Cancer
Late Breaking Abstract – ESMO Congress 2024: IMFINZI® Along with Neoadjuvant Chemotherapy Improves Survival in Muscle Invasive Bladder Cancer
FDA Approves RYBREVANT® plus Chemotherapy for EGFR-Mutated NSCLC
FDA Approves SARCLISA® with VRd Regimen for Newly Diagnosed Multiple Myeloma
Ivonescimab may be Superior to Pembrolizumab as First-Line Treatment in NSCLC
Optimal Approach for Integrating Immune Checkpoint Inhibitors in Early-Stage Breast Cancer: A Meta-Analysis